226.76MMarket Cap-1774P/E (TTM)
2.820High2.690Low864.98KVolume2.740Open2.650Pre Close2.38MTurnover1.16%Turnover RatioLossP/E (Static)82.46MShares6.13052wk High2.04P/B204.53MFloat Cap2.45052wk Low--Dividend TTM74.38MShs Float28.300Historical High--Div YieldTTM4.91%Amplitude2.005Historical Low2.753Avg Price1Lot Size
Sutro Biopharma Stock Forum
Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
- 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
- 35% overal...
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma (NASDAQ: STRO) has initiated the REFRαME-L1 global Phase 2 study of luveltamab tazevibulin (luvelta) for non-small cell lung cancer (NSCLC)patients with Folate Receptor-α (FRα) expressing tumors.
The trial is now open for enrollment, with initial data expected in H1 2025. Luvelta, an antibody drug conjugate (ADC), shows promise...
Sutro Biopharma Announces Initiation of RefrΑMe-L1 Phase 2 Trial With Luvelta for Patients With Non-Small Cell Lung Cancer
Title: Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (b...
Dow Jones· 2 mins ago
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
No comment yet